Teva recently halted its Ajovy clinical development.
Teva recently halted its Ajovy clinical development.
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorisation.
The news comes shortly after AZ announced positive results from a late-stage trial of the drug.
IQVIA have been confirmed to host the finals days for the 2019 PharmaTimes Marketer of the Year and also the Sales Awards at their offices in Reading.
The sales numbers were boosted by oncology drugs such as Tagrisso, Imfinzi and Lynparza.
The drug is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator.
Scientists are “re-imagining ultrasound technology to develop a treatment that can liquefy cancer cells in the body using microscopic bubbles”.
The application is for cabotegravir and Edurant (rilpivirine) as the first monthly, injectable treatment for HIV.
Rates have increased by more than a third (35%) for women and by almost three-fifths (55%) for men.
But the organisation says it will “need more details of exactly how this will be achieved”.
The FDA initially cited insufficient data and refused to accept the initial submission in August 2017.
Increasing health span has been adopted as a policy objective by the UK Government in the Industrial Strategy’s “Ageing Society”.
The treatment reduces the risk of disease progression or death in such patients by 70% vs placebo.
Stelara, Keytruda and Tecentriq were also among the extensions of therapeutic indication.
The funding will support 10,000 young people from all backgrounds to get a career in the NHS.